cro.directory
← Compare landing

Atheln, Inc. vs Certara

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryAtheln, Inc.Certara
SummaryAtheln provides customized strategic and operational consulting across product development, CMC, nonclinical, clinical, regulatory, and commercial services for pharma, biotech, and medtech clients.Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
Services
  • Clinical Trial Services
  • Clinical Operations
  • Biostatistics & Statistical Programming
  • Medical Writing
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Analytical Method Development & Validation
  • Translational Research
  • Discovery Research
  • Target Identification & Validation
  • High-Throughput Screening
  • Medicinal Chemistry
  • Computational & In-Silico Drug Discovery
  • Preclinical In Vitro Studies
  • In Vitro Pharmacology
  • In Vitro ADME / DMPK
  • Safety Pharmacology
  • Genetic Toxicology
  • Preclinical In Vivo Studies
  • In Vivo Efficacy Models
  • In Vivo PK / PD Studies
  • GLP Toxicology
  • Bioanalysis
  • LC-MS Bioanalysis (Small Molecule)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • Biomarker Assays
  • Clinical Trial Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Data Management & eClinical
  • Biostatistics & Statistical Programming
  • Medical Writing
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Small Molecule
  • Biologics (Other)
  • Oligonucleotide
  • Peptide
  • Radiopharmaceutical
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • Oligonucleotide
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Peptide
  • Vaccine
Indications
  • Ophthalmology
  • Oncology
  • Immunology
  • Neurology
  • Psychiatry
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Respiratory
  • Dermatology
  • Ophthalmology
  • Gastroenterology
  • Nephrology
  • Women's Health
Phases
  • Discovery
  • Preclinical (General)
  • Preclinical (IND-Enabling)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Discovery
  • Preclinical (General)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Preclinical (IND-Enabling)
  • Real-World Evidence (RWE) / Registries
Sourcing models
  • Full-Service Outsourcing (FSO)
  • Functional Service Provider (FSP)
  • Full-Service Outsourcing (FSO)
  • Functional Service Provider (FSP)
LocationsData not yet provided.
  • Global network
  • Global presence, 30 countries
  • Global presence, Multiple, 30 countries, Global
  • Global presence, Multiple, 30+ countries
  • Global presence, Multiple, 30 countries, International
  • Headquarters, Radnor, Pennsylvania, United States
  • Global presence, 30 countries
  • Global presence, 30+ countries
CertificationsData not yet provided.Data not yet provided.

Find similar companies

Atheln, Inc. alternatives · Certara alternatives

Markdown mirror: /compare/athelnbiomed/certara.md